K. Stephens

A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials

J. Provenzale, E. Major, D. Clifford, 2018, Drug Safety.

Risk Assessment and Minimization for Progressive Multifocal Leukoencephalopathy (PML RAMP): A Program to Assess for Potential Early Signs and Symptoms of PML during Clinical Development of Vedolizumab: 1673

J. Provenzale, E. Major, D. Clifford, 2013 .

Vedolizumab as induction and maintenance therapy for Crohn's disease.

Kristin Stephens, Serap Sankoh, Paul Rutgeerts, 2013, The New England journal of medicine.

Vedolizumab Maintenance Therapy for Crohnʼs Disease: Results of GEMINI II, a Randomized, Placebo-Controlled, Double-Blind, Multi-center Phase 3 Trial: 1542

Jing Xu, P. Rutgeerts, S. Hanauer, 2012 .

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

J. Carulli, M. McKeown, M. Eaton, 2022, Blood advances.

Trial design of a first-in-human phase 1 evaluation of SY-1365, a first-in-class selective CDK7 inhibitor, with initial expansions in ovarian and breast cancer.

A. Tolcher, G. Shapiro, D. Juric, 2018 .

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment

M. McKeown, J. Cortes, D. Steensma, 2017 .

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

J. Cortes, J. Liesveld, A. Raza, 2018, Blood.